CHARACTERIZATION AND TREATMENT OF A NOVEL MOUSE MODEL OF TSC-ASSOCIATED AUTISM

Tuberous sclerosis complex (TSC) is a dominant tumor suppressor disorder caused by mutations in either TSC1 or TSC2. The proteins of these genes form a complex to inhibit the mammalian target of rapamycin complex 1 (mTORC1), which controls protein translation and cell growth. TSC causes substantial neuropathology, often leading to autism spectrum disorders (ASDs) in up to 60% of patients. The anatomic and neurophysiologic links between these two disorders are not well understood. However, both disorders share cerebellar abnormalities. Therefore, we have characterized a novel mouse model in which the Tsc2 gene was selectively deleted from cerebellar Purkinje cells (Tsc2f/-;Cre). These mice exhibit progressive Purkinje cell degeneration. Since loss of Purkinje cells is a well-reported postmortem finding in patients with ASD, we conducted a series of behavior tests to assess if Tsc2f/-;Cre mice displayed autistic-like deficits. Using the three chambered social choice assay, we found that Tsc2f/-;Cre mice showed behavioral deficits, exhibiting no preference between a stranger mouse and an inanimate object, or between a novel and a familiar mouse. Tsc2f/-;Cre mice also demonstrated increased repetitive behavior as assessed with marble burying activity. Altogether, these results demonstrate that loss of Tsc2 in Purkinje cells in a haploinsufficient background lead to behavioral deficits that are characteristic of human autism. Therefore, Purkinje cells loss and/or dysfunction may be an important link between TSC and ASD. Additionally, we have examined some of the cellular mechanisms resulting from mutations in Tsc2 leading to Purkinje cell death. Loss of Tsc2 led to upregulation of mTORC1 and increased cell size. As a consequence of increased protein synthesis, several cellular stress pathways were upregulated. Principally, these included altered calcium signaling, oxidative stress, and ER stress. Likely as a consequence of ER stress, there was also upregulation of ubiquitin and autophagy. Excitingly, treatment with an mTORC1 inhibitor, rapamycin attenuated mTORC1 activity and prevented Purkinje cell death by reducing of calcium signaling, the ER stress response, and ubiquitin. Remarkably, rapamycin treatment also reversed the social behavior deficits, thus providing a promising potential therapy for TSC-associated ASD.

A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1

Tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) by the insulin receptor permits this docking protein to interact with signaling proteins that promote insulin action. Serine phosphorylation uncouples IRS-1 from the insulin receptor, thereby inhibiting its tyrosine phosphorylation and insulin signaling. For this reason, there is great interest in identifying serine/threonine kinases for which IRS-1 is a substrate. Tumor necrosis factor (TNF) inhibited insulin-promoted tyrosine phosphorylation of IRS-1 and activated the Akt/protein kinase B serine-threonine kinase, a downstream target for phosphatidylinositol 3-kinase (PI 3-kinase). The effect of TNF on insulin-promoted tyrosine phosphorylation of IRS-1 was blocked by inhibition of PI 3-kinase and the PTEN tumor suppessor, which dephosphorylates the lipids that mediate PI 3-kinase functions, whereas constitutively active Akt impaired insulin-promoted IRS-1 tyrosine phosphorylation. Conversely, TNF inhibition of IRS-1 tyrosine phosphorylation was blocked by kinase dead Akt. Inhibition of IRS-1 tyrosine phosphorylation by TNF was blocked by rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), a downstream target of Akt. mTOR induced the serine phosphorylation of IRS-1 (Ser-636/639), and such phosphorylation was inhibited by rapamycin. These results suggest that TNF impairs insulin signaling through IRS-1 by activation of a PI 3-kinase/Akt/mTOR pathway, which is antagonized by PTEN.

Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli

To investigate the mechanism by which beta-hydroxy-beta-methylbutyrate (HMB) attenuates the depression of protein synthesis in the skeletal muscle of cachectic mice, a study has been carried out in murine myotubes in the presence of proteolysis-inducing factor (PIF). PIF inhibited protein synthesis by 50% within 4 h, and this was effectively attenuated by HMB (25-50 muM). HMB (50 muM) alone stimulated protein synthesis, and this was attenuated by rapamycin (27 nM), an inhibitor of mammalian target of rapamycin (mTOR). Further evidence for an involvement of this pathway was shown by an increased phosphorylation of mTOR, the 70-kDa ribosomal S6 kinase (p70(S6k)), and initiation factor 4E-binding protein (4E-BP1) and an increased association of eukaryotic initiation factor 2 (eIF4E) with eIF4G. PIF alone induced a transient (1-2 h) stimulation of phosphorylation of mTOR and p70(S6k). However, in the presence of HMB, phosphorylation of mTOR, p70(S6k), and 4E-BP1 was increased, and inactive 4E-BP1-eIF4E complex was reduced, whereas the active eIF4G.eIF4E complex was increased, suggesting continual stimulation of protein synthesis. HMB alone reduced phosphorylation of elongation factor 2, but this effect was not seen in the presence of PIF. PIF induced autophosphorylation of the double-strand RNA-dependent protein kinase (PKR), leading to phosphorylation of eIF2 on the alpha-subunit, which would inhibit protein synthesis. However, in the presence of HMB, phosphorylation of PKR and eIF2alpha was attenuated, and this was also observed in skeletal muscle of cachectic mice administered HMB (0.25 g/kg). These results suggest that HMB attenuates the depression of protein synthesis by PIF in myotubes through multiple mechanisms.

Involvement of phosphoinositide 3-kinase and Akt in the induction of muscle protein degradation by proteolysis-inducing factor

In the present study the role of Akt/PKB (protein kinase B) in PIF- (proteolysis-inducing factor) induced protein degradation has been investigated in murine myotubes. PIF induced transient phosphorylation of Akt at Ser(473) within 30 min, which was attenuated by the PI3K (phosphoinositide 3-kinase) inhibitor LY294002 and the tyrosine kinase inhibitor genistein. Protein degradation was attenuated in myotubes expressing a dominant-negative mutant of Akt (termed DNAkt), compared with the wild-type variant, whereas it was enhanced in myotubes containing a constitutively active Akt construct (termed MyrAkt). A similar effect was observed on the induction of the ubiquitin-proteasome pathway. Phosphorylation of Akt has been linked to up-regulation of the ubiquitin-proteasome pathway through activation of NF-kappaB (nuclear factor kappaB) in a PI3K-dependent process. Protein degradation was attenuated by rapamycin, a specific inhibitor of mTOR (mammalian target of rapamycin), when added before, or up to 30 min after, addition of PIF. PIF induced transient phosphorylation of mTOR and the 70 kDa ribosomal protein S6 kinase. These results suggest that transient activation of Akt results in an increased protein degradation through activation of NF-kappaB and that this also allows for a specific synthesis of proteasome subunits.

BSTA Promotes mTORC2-Mediated Phosphorylation of Akt1 to Suppress Expression of FoxC2 and Stimulate Adipocyte Differentiation

Phosphorylation and activation of Akt1 is a crucial signaling event that promotes adipogenesis. However, neither the complex multistep process that leads to activation of Akt1 through phosphorylation at Thr308 and Ser473 nor the mechanism by which Akt1 stimulates adipogenesis is fully understood. We found that the BSD domain–containing signal transducer and Akt interactor (BSTA) promoted phosphorylation of Akt1 at Ser473 in various human and murine cells, and we uncovered a function for the BSD domain in BSTA-Akt1 complex formation. The mammalian target of rapamycin complex 2 (mTORC2) facilitated the phosphorylation of BSTA and its association with Akt1, and the BSTA-Akt1 interaction promoted the association of mTORC2 with Akt1 and phosphorylation of Akt1 at Ser473 in response to growth factor stimulation. Furthermore, analyses of bsta gene-trap murine embryonic stem cells revealed an essential function for BSTA and phosphorylation of Akt1 at Ser473 in promoting adipocyte differentiation, which required suppression of the expression of the gene encoding the transcription factor FoxC2. These findings indicate that BSTA is a molecular switch that promotes phosphorylation of Akt1 at Ser473 and reveal an mTORC2-BSTA-Akt1-FoxC2–mediated signaling mechanism that is critical for adipocyte differentiation.

EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma

Background We hypothesised that alternating inhibitors of the vascular endothelial growth factor receptor (VEGFR) and mammalian target of rapamycin pathways would delay the development of resistance in advanced renal cell carcinoma (aRCC). Patients and methods A single-arm, two-stage, multicentre, phase 2 trial to determine the activity, feasibility, and safety of 12-week cycles of sunitinib 50 mg daily 4 weeks on / 2 weeks off, alternating with everolimus 10 mg daily for 5 weeks on / 1 week off, until disease progression or prohibitive toxicity in favourable or intermediate-risk aRCC. The primary end point was proportion alive and progression-free at 6 months (PFS6m). The secondary end points were feasibility, tumour response, overall survival (OS), and adverse events (AEs). The correlative objective was to assess biomarkers and correlate with clinical outcome. Results We recruited 55 eligible participants from September 2010 to August 2012. Demographics: mean age 61, 71% male, favourable risk 16%, intermediate risk 84%. Cycle 2 commenced within 14 weeks for 80% of participants; 64% received ≥22 weeks of alternating therapy; 78% received ≥22 weeks of any treatment. PFS6m was 29/55 (53%; 95% confidence interval [CI] 40% to 66%). Tumour response rate was 7/55 (13%; 95% CI 4% to 22%, all partial responses). After median follow-up of 20 months, 47 of 55 (86%) had progressed with a median progression-free survival of 8 months (95% CI 5–10), and 30 of 55 (55%) had died with a median OS of 17 months (95% CI 12–undefined). AEs were consistent with those expected for each single agent. No convincing prognostic biomarkers were identified. Conclusions The EVERSUN regimen was feasible and safe, but its activity did not meet pre-specified values to warrant further research. This supports the current approach of continuing anti-VEGF therapy until progression or prohibitive toxicity before changing treatment.

Role of T cells in malnutrition and obesity.

Nutritional status is critically important for immune cell function. While obesity is characterized by inflammation that promotes metabolic syndrome including cardiovascular disease and insulin resistance, malnutrition can result in immune cell defects and increased risk of mortality from infectious diseases. T cells play an important role in the immune adaptation to both obesity and malnutrition. T cells in obesity have been shown to have an early and critical role in inducing inflammation, accompanying the accumulation of inflammatory macrophages in obese adipose tissue, which are known to promote insulin resistance. How T cells are recruited to adipose tissue and activated in obesity is a topic of considerable interest. Conversely, T cell number is decreased in malnourished individuals, and T cells in the setting of malnutrition have decreased effector function and proliferative capacity. The adipokine leptin, which is secreted in proportion to adipocyte mass, may have a key role in mediating adipocyte-T cell interactions in both obesity and malnutrition, and has been shown to promote effector T cell function and metabolism while inhibiting regulatory T cell proliferation. Additionally, key molecular signals are involved in T cell metabolic adaptation during nutrient stress; among them, the metabolic regulator AMP kinase and the mammalian target of rapamycin have critical roles in regulating T cell number, function, and metabolism. In summary, understanding how T cell number and function are altered in obesity and malnutrition will lead to better understanding of and treatment for diseases where nutritional status determines clinical outcome.

The liver kinase B1 is a central regulator of T cell development, activation, and metabolism.

T cell activation leads to engagement of cellular metabolic pathways necessary to support cell proliferation and function. However, our understanding of the signal transduction pathways that regulate metabolism and their impact on T cell function remains limited. The liver kinase B1 (LKB1) is a serine/threonine kinase that links cellular metabolism with cell growth and proliferation. In this study, we demonstrate that LKB1 is a critical regulator of T cell development, viability, activation, and metabolism. T cell-specific ablation of the gene that encodes LKB1 resulted in blocked thymocyte development and a reduction in peripheral T cells. LKB1-deficient T cells exhibited defects in cell proliferation and viability and altered glycolytic and lipid metabolism. Interestingly, loss of LKB1 promoted increased T cell activation and inflammatory cytokine production by both CD4(+) and CD8(+) T cells. Activation of the AMP-activated protein kinase (AMPK) was decreased in LKB1-deficient T cells. AMPK was found to mediate a subset of LKB1 functions in T lymphocytes, as mice lacking the α1 subunit of AMPK displayed similar defects in T cell activation, metabolism, and inflammatory cytokine production, but normal T cell development and peripheral T cell homeostasis. LKB1- and AMPKα1-deficient T cells each displayed elevated mammalian target of rapamycin complex 1 signaling and IFN-γ production that could be reversed by rapamycin treatment. Our data highlight a central role for LKB1 in T cell activation, viability, and metabolism and suggest that LKB1-AMPK signaling negatively regulates T cell effector function through regulation of mammalian target of rapamycin activity.

hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase

Mammalian cells respond to nutrient deprivation by inhibiting energy consuming processes, such as proliferation and protein synthesis, and by stimulating catabolic processes, such as autophagy. p70 S6 kinase (S6K1) plays a central role during nutritional regulation of translation. S6K1 is activated by growth factors such as insulin, and by mammalian target of rapamycin (mTOR), which is itself regulated by amino acids. The Class IA phosphatidylinositol (PI) 3-kinase plays a well recognized role in the regulation of S6K1. We now present evidence that the Class III PI 3-kinase, hVps34, also regulates S6K1, and is a critical component of the nutrient sensing apparatus. Overexpression of hVps34 or the associated hVps15 kinase activates S6K1, and insulin stimulation of S6K1 is blocked by microinjection of inhibitory anti-hVps34 antibodies, overexpression of a FYVE domain construct that sequesters the hVps34 product PI(3) P, or small interfering RNA-mediated knock-down of hVps34. hVps34 is not part of the insulin input to S6K1, as it is not stimulated by insulin, and inhibition of hVps34 has no effect on phosphorylation of Akt or TSC2 in insulin-stimulated cells. However, hVps34 is inhibited by amino acid or glucose starvation, suggesting that it lies on the nutrient-regulated pathway to S6K1. Consistent with this, hVps34 is also inhibited by activation of the AMP-activated kinase, which inhibits mTOR/S6K1 in glucose-starved cells. hVps34 appears to lie upstream of mTOR, as small interfering RNA knock- down of hVps34 inhibits the phosphorylation of another mTOR substrate, eIF4E-binding protein-1 (4EBP1). Our data suggest that hVps34 is a nutrient-regulated lipid kinase that integrates amino acid and glucose inputs to mTOR and S6K1.

Unspliced X-box-binding Protein 1 (XBP1) Protects Endothelial Cells from Oxidative Stress through Interaction with Histone Deacetylase 3

It is well-known that atherosclerosis occurs geographically at branch points where disturbed flow predisposes to the development of plaque via triggering of oxidative stress and inflammatory reactions. In this study, we found that disturbed flow activated anti-oxidative reactions via up-regulating heme oxygenase 1 (HO-1) in an X-box binding protein 1 (XBP1) and histone deacetylase 3 (HDAC3)-dependent manner. Disturbed flow concomitantly up-regulated the unspliced XBP1 (XBP1u) and HDAC3 in a vascular endothelial growth factor receptor (VEGFR) and PI3K/Akt dependent manner. The presence of XBP1 was essential for the up-regulation of HDAC3 protein. Over-expression of XBP1u and/or HDAC3 activated Akt1 phosphorylation, Nrf2 protein stabilization and nuclear translocation, and HO-1 expression. Knockdown of XBP1u decreased the basal level and disturbed flow-induced Akt1 phosphorylation, Nrf2 stabilization and HO-1 expression. Knockdown of HDAC3 ablated XBP1u-mediated effects. The mammalian target of rapamycin complex 2 (mTORC2) inhibitor, AZD2014, ablated XBP1u or HDAC3 or disturbed flow-mediated Akt1 phosphorylation, Nrf2 nuclear translocation and HO-1 expression. Neither actinomycin D nor cycloheximide affected disturbed flow-induced up-regulation of Nrf2 Protein. Knockdown of Nrf2 abolished XBP1u or HDAC3 or disturbed flow-induced HO-1 up-regulation. Co-immunoprecipitation assays demonstrated that XBP1u physically bound to HDAC3 and Akt1. The region of amino acids 201 to 323 of the HDAC3 protein was responsible for the binding to XBP1u. Double immunofluorescence staining revealed that the interactions between Akt1 and mTORC2, Akt1 and HDAC3, Akt1 and XBP1u, HDAC3 and XBP1u occurred in the cytosol. Thus, we demonstrate that XBP1u and HDAC3 exert a protective effect on disturbed flow-induced oxidative stress via up-regulation of mTORC2-dependent Akt1 phosphorylation and Nrf2-mediated HO-1 expression.

Autophagy in hypothalamic cells: role of Neuropeptide Y

Dissertação de mest.Ciências Biomédicas. Departamento de Ciências Biomédicas e Medicina, Univ. do Algarve, 2011

Caspase-mediated cleavage of raptor participates in the inactivation of mTORC1 during cell death.

The mammalian target of rapamycin complex 1 (mTORC1) is a highly conserved protein complex regulating key pathways in cell growth. Hyperactivation of mTORC1 is implicated in numerous cancers, thus making it a potential broad-spectrum chemotherapeutic target. Here, we characterized how mTORC1 responds to cell death induced by various anticancer drugs such rapamycin, etoposide, cisplatin, curcumin, staurosporine and Fas ligand. All treatments induced cleavage in the mTORC1 component, raptor, resulting in decreased raptor-mTOR interaction and subsequent inhibition of the mTORC1-mediated phosphorylation of downstream substrates (S6K and 4E-BP1). The cleavage was primarily mediated by caspase-6 and occurred at two sites. Mutagenesis at one of these sites, conferred resistance to cell death, indicating that raptor cleavage is important in chemotherapeutic apoptosis.

La Rapamycine inhibe l’expression de l’ARNm de l’ADAMTS-4 induit par les cytokines dans les chondrocytes articulaires

Introduction: Durant la pathogenèse d’ostéoarthrose (OA), les cytokines pro-inflammatoires IL-1β (Interleukin-1 beta) et TNF-α (Tumor necrosis factor alpha) stimulent la dégradation des agrécanes par l’aggrécanase-1 ou ADAMTS-4 (a disintegrin and metalloproteinase with thrombospondin motif). Ces cytokines peuvent stimuler plusieurs voies de signalisation conduisant ainsi à l’augmentation de l’expression des ADAMTS dans les chondrocytes humains. Les TIMPs (tissue inhibitor of metalloproteinases) présentent des inhibiteurs endogènes de l’ADAMTS. Nous avons démontré que la Rapamycine (un immunosuppresseur et un inhibiteur du mamalian target of Rapamycin (mTOR)) peut avoir des effets bénéfiques dans cette pathologie. Notre étude examine l’effet de la Rapamycine sur l’expression de l’ADAMTS-4 induit par les cytokines, son implication dans certaines voies de signalisation, et son effet sur l’expression du TIMP-3. Méthodes: Des chondrocytes normaux sont traités avec la Rapamycine seule ou stimulés aussi avec l’IL-1β et le TNF-α. Les effets de la Rapamycine sur l’expression de l’ADAMTS-4 et du TIMP-3 ont été étudiés par l’analyse RT-PCR et l’activité enzymatique a été étudiée par la technique d’ELISA. Les effets de la Rapamycine sur certaines voies de signalisation ont été étudiés par le Western blot. Résultats: Nous avons trouvé que la Rapamycine inhibe l’expression de l’ARNm de l’ADAMTS-4 induit par les cytokines pro-inflammatoires dans les chondrocytes humains. L’activité enzymatique de l’ADAMTS-4 induit par l’IL-1β a été légèrement diminuée par la Rapamycine. En plus, cette dernière a montré de différents effets sur plusieurs voies de signalisation stimulées par l’IL-1β et le TNF-α telles que les voies des MAPKs (Mitogen activated protein kinase), de l’AKT, et de la p70 S6 kinase. La Rapamycine a inhibé partiellement l’activation de la phosphorylation de l’ERK1/2 MAPK (extracellular signal-regulated protein kinase MAPK) en présence du TNF-α seulement. En outre, la Rapamycine a inhibé la phosphorylation des protéines p38 MAPK, JNK (c-Jun N-terminal kinase), et AKT activée par l’IL-1β seulement. En plus, la phosphorylation de la protéine p70 S6K stimulée par l’IL-1β et le TNF-α a été inhibée par la Rapamycine. D’autre part, nous avons démontré que le niveau du TIMP-3 a été augmenté en présence de la Rapamycine. Conclusion: Ces résultats suggèrent que la Rapamycine peut bloquer l’action de l’ADAMTS-4 via l’inhibition de l’activation des MAPKs, de l’AKT, et de la p70 S6K. La Rapamycine pourrait ainsi être considérée pour la prévention de la perte du cartilage chez les patients ostéoarthritiques.

Caractérisation des processus moléculaires impliqués dans l’activation de la protéine IKKbeta par l'angiotensine II et son rôle dans la réponse phénotypique des CMLV.

Le système rénine-angiotensine-aldostérone (SRAA) régule l’homéostasie de la contraction des artères. Or, suivant la liaison de l’angiotensine II (Ang II) à son récepteur AT1, le SRAA est également impliqué dans l’activation de voies de signalisation à l’origine de l’inflammation et de l’hypertrophie des cellules musculaires lisses vasculaires (CMLV), soit deux processus participant au remodelage vasculaire caractéristique de diverses maladies cardiovasculaires, telles l’hypertension et l’athérosclérose. Ces pathologies sont les premières causes de mortalité naturelle en Amérique et les traitements les ciblant ne sont pas optimaux puisqu’ils visent seulement quelques facteurs de risque qui leur sont associés. Ainsi, la détermination des effecteurs intracellulaires régulant ces voies délétères est nécessaire à l'identification de nouvelles cibles thérapeutiques. L’inflammation Ang II-dépendante dans les CMLV est attribuée au facteur de transcription nuclear factor-kappa B (NF-κB). Cependant, les processus moléculaires couplant le récepteur AT1 à son activation sont peu caractérisés. L’étude abordant cette question démontre in vitro que NF-κB est activé par la protéine IκB kinase β (IKKβ) dans les CMLV exposées à l’Ang II et que cette kinase est régulée par deux voies de signalisation indépendantes, mais complémentaires afin d’assurer son activation rigoureuse et soutenue. L’une des voies est précoce et dépend des seconds messagers ainsi que de deux nouveaux effecteurs sous-jacents au récepteur AT1, soit la E3 ligase TNF receptor-associated factor 6 (TRAF6) et la IKK kinase transforming growth factor-beta-activated kinase 1 (TAK1) tandis que la seconde est tardive et résulte de la signalisation mitogen-activated protein kinase kinase 1/2 (MEK1/2) - extracellular signal-regulated kinase 1/2 (ERK1/2) - ribosomal S6 kinase (RSK). L’inhibition conjointe de ces voies abroge complètement la réponse inflammatoire, ce qui indique qu’elles en sont la seule source. Ainsi, l’inhibition d’IKKβ pourrait suffire à contrer l’inflammation impliquée dans le remodelage vasculaire associé à une suractivation du SRAA. Une découverte des plus novatrices découle de cette étude, qui veut que la E3 ligase TRAF6 est un nouvel effecteur des récepteurs couplés aux protéines G et est à l’origine de la formation d’un nouveau type de second messager, soit des chaînes libres de poly-ubiquitines. Les mécanismes moléculaires à la base de l’hypertrophie Ang II-dépendante dans les CMLV sont également peu définis. Or, suivant la parution d’un article démontrant qu’IKKβ dans les cellules cancéreuses participe aux mécanismes d’initiation de la traduction en réponse au facteur de nécrose tumorale α (TNFα) via la phosphorylation de la protéine Tuberous sclerosis 1 (TSC1) et donc l’activation du complexe mammalian target of rapamycin (mTORC1), une hypothèse a été émise selon laquelle cette kinase serait impliquée dans la synthèse protéique Ang II-dépendante dans les CMLV. Les expériences effectuées in vitro dans des CMLV exposées à l’Ang II démontrent qu’IKKβ induit la phosphorylation de TSC1 ainsi que l’activation de mTORC1 et de ses substrats S6 kinase 1 (S6K1) et translational regulators eukaryotic translation initiation factor 4E-binding protein (4E-BP1), deux protéines impliquées directement dans l’hypertrophie. Par ailleurs, la synthèse protéique au niveau des CMLV exposées à l’Ang II est réduite de 75% suivant la diminution de l’expression d’IKKβ et suivant la surexpression d’un mutant de TSC1 dont le site consensus d’IKKβ a été modifié, faisant de cette kinase un médiateur majeur au niveau de ce processus. Ainsi, in vitro IKKβ en réponse à l’Ang II est en amont de deux processus impliqués dans un remodelage vasculaire à l’origine de maladies cardiovasculaires. De plus, plusieurs facteurs de risque de ces pathologies convergent à l’activation d’IKKβ, ce qui en fait une cible thérapeutique particulièrement attrayante. Qui plus est, l’administration d’un inhibiteur d’IKKβ à des rats diminue non seulement la synthèse protéique dépendante de l’Ang II au niveau de l’aorte et des artères mésentériques, mais également la synthèse de la protéine pro-inflammatoire VCAM-1 par les cellules composant l’aorte, ce qui confirme son envergure en tant que cible.

Mécanismes moléculaires régulant la pathologie dendritique dans la rétine adulte lésée in vivo

Les dendrites sont essentielles pour la réception et l’intégration des stimuli afférents dans les neurones. De plus en plus d’évidences d’une détérioration dendritique sont associées à une axonopathie dans les maladies neurodégénératives. Le glaucome dont la physiopathologie est caractérisée par une détérioration progressive et irréversible des cellules ganglionnaires de la rétine (CGRs) est la première cause de cécité irréversible dans le monde. Son évolution est associée à un amincissement graduel des axones et à l’atrophie des somas des CGRs. La majorité des études de neuroprotection des neuropathies rétiniennes visent la survie et la protection des somas et des axones. Des études récentes ont démontré des changements dendritiques associés à cette pathologie, toutefois les mécanismes moléculaires les régulant sont méconnus. L’hypothèse principale de ma thèse stipule qu’une lésion axonale entraîne des altérations précoces des structures dendritiques. L’identification de voies de signalisation régulant ces changements permettrait d’élaborer des stratégies de neuroprotection et de rétablir la fonction de ces neurones. Dans la première étude, nous avons examiné l’effet précoce d’une lésion axonale aigüe sur la morphologie dendritique des CGRs in vivo. En utilisant des souris transgéniques exprimant la protéine fluorescente jaune (YFP) soumises à une axotomie, nous avons démontré un rétrécissement de l’arbre dendritique des CGRs et une diminution sélective de l’activité de mTOR avant le début de la mort des CGRs lésées. Aussi nous avons démontré une augmentation de l’expression de la protéine Regulated in development and DNA damage response 2 (REDD2), un régulateur négatif en amont de la protéine mTOR en réponse à la lésion du nerf optique in vivo. Nous avons démontré que la réactivation de mTOR par l’inhibition de l’expression de REDD2 préserve les arbres dendritiques des CGRs adultes. En effet, l’injection de petits ARN d’interférence contre la REDD2 (siREDD2) stimule l’activité de mTOR dans les CGRs lésées et augmente significativement la longueur et la surface dendritique totale. De plus, la rapamycine, un inhibiteur de mTOR, inhibe complètement l’effet du siREDD2 sur la croissance et l’élaboration des dendrites. L’analyse électrophysiologique des CGRs démontre une augmentation de l’excitabilité des CGRs lésées qui est restaurée en présence du siREDD2. Par ailleurs, des données récentes ont mis en évidence l’implication de la neuro-inflammation dans le glaucome, caractérisée par une augmentation de cytokines pro-inflammatoires dont principalement le facteur de nécrose tumorale (TNFα). Ainsi dans la deuxième étude nous avons examiné l’effet du TNF exogène sur la morphologie de l’arbre dendritique des CGRs et commencé l’étude des mécanismes moléculaires sous-jacents à ces changements. Nos résultats démontrent que l’injection de TNF recombinante dans le vitrée induit une rétraction dendritique précoce qui corrèle à une réduction de phospho-S6 suggérant l’implication de mTOR dans ces CGRs lésées. Ainsi, les études présentées dans cette thèse mettent en évidence un nouveau rôle de mTOR dans la stabilité et le maintien des dendrites de neurones rétiniennes adultes. Ces études ont aussi démontré l’effet précoce de stress direct ou indirect, c’est-à-dire l’axotomie et le TNFα respectivement sur la pathologie dendritique et sur leur effet sur la fonction neuronale.